Search Results
Your search for The ,The matches 36005 pages
Showing 1 - 50Clinical Trials May Misrepresent True Thromboembolic Risks From Cancer Drugs
Researchers have identified that the reporting of venous and arterial thrombotic events in cancer clinical trials is inconsistent and potentially inaccurate, according to a comments article published in the Journal of Clinical Oncology.1 “Mandatory and uniform reporting of all [venous and arterial...
Cumulative Incidence of Advanced Breast Cancer in Japanese Women Aged 40 to 49 Years With Addition of Ultrasonography to Mammography Screening
As reported in The Lancet by Harada-Shoji et al, the Japanese J-START trial showed that adjunctive ultrasonography was associated with a reduced cumulative incidence of advanced breast cancer vs mammography alone in screening of asymptomatic women aged 40 to 49 years. Initial reports from the trial ...
HPV Vaccination Protection From Cervical Cancer Sustained Long Term
Quadrivalent human papillomavirus (HPV) vaccination led to a significantly reduced risk of invasive cervical cancer that was sustained through long-term follow-up, according to the results of a Swedish nationwide, register-based cohort study published in The BMJ. “This study provides evidence of...
Five-Year Outcomes With First-Line Nivolumab Plus Ipilimumab in Unresectable Pleural Mesothelioma
As reported in the Journal of Clinical Oncology by Scherpereel et al, 5-year findings from the phase III CheckMate 743 trial showed continued overall survival benefit of first-line nivolumab plus ipilimumab vs chemotherapy in patients with unresectable pleural mesothelioma. Study Details In the...
FDA Approves Teclistamab and Daratumumab For Relapsed or Refractory Multiple Myeloma
On March 5, 2026, the U.S. Food and Drug Administration (FDA) approved teclistamab (Tecvayli) in combination with daratumumab hyaluronidase-fihj for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a...
Activity Observed with Novel KRAS Inhibitor in Pancreatic Cancer
A novel KRAS G12D inhibitor produced disease control in almost 80% of patients with heavily pretreated advanced or metastatic KRAS G12D–mutated pancreatic cancer in an early-phase study reported at the 2026 ASCO Gastrointestinal (GI) Cancers Symposium.1 Of 41 evaluable patients treated with...
Short-Term Vaginal Estrogen Therapy Does Not Increase Risks of Endometrial Cancer Recurrence
Short-term exposure to low-dose vaginal estrogen therapy may relieve some symptoms of menopause for younger survivors of endometrial cancer without increasing the risk of endometrial cancer recurrence, according to findings from a study published in Menopause. “Early detection and improved,...
Accuracy of Molecular Inference–Based AI Model for CNS Tumor Diagnosis
In a retrospective study reported in The Lancet Oncology, Lalchungnunga et al tested the classification accuracy of a molecular inference–based artificial intelligence (AI) model (Neuropath-AI) in central nervous system (CNS) tumor diagnosis. Study Details The multi-institutional study included...
Ablation vs Surgery for Small Kidney Tumors
A large national study in Denmark following nearly 1,900 patients over almost a decade found that minimally invasive ablation is as effective as surgery for treating small kidney cancers, with faster recovery and fewer complications. Results of the study were published by Ahrenfeldt et al in...
Social Cue Prompts Reduce Sharing of Cancer Treatment Misinformation
Prompts on posts with social cues—such as messages indicating how many users have flagged a post—and clear platform review policies may encourage intervention and reduce sharing of cancer treatment misinformation on social media, according to Lazard et al, who reported findings from their online...
Colorectal Cancer: ACS Report Shows Increasing Incidence, Mortality Rates in Younger Adults
Findings from the American Cancer Society's triennial report, Colorectal Cancer Statistics, 2026, show that rates of colorectal cancer are decreasing in older adults; however, rates of colorectal cancer incidence in younger adults continue to increase, with a greater proportion of these cancers...
Research Suggests AI Pathology Models May Take Unreliable 'Shortcuts' to Identify Cancer Biomarkers
Artificial intelligence (AI) tools that detect molecular biomarker status from histologic images may be dependent upon correlational relationships with clinicopathologic features, preventing the models from learning the true causal effect of the biomarker, according to findings published in Nature...
Matthew D. Galsky, MD, FASCO, on Muscle-Invasive Bladder Cancer: Enfortumab Vedotin and Pembrolizumab
Matthew D. Galsky, MD, FASCO, of Mount Sinai Tisch Cancer Center, discusses findings from the randomized phase III KEYNOTE-B15/EV-304 study, which is evaluating neoadjuvant and adjuvant enfortumab vedotin plus pembrolizumab followed by radical cystectomy plus pelvic lymph node dissection vs...
Thomas Powles, MD, PhD, FCRP, on a Novel Antibody-Drug Conjugate in Previously Treated Advanced Urothelial Cancer
Thomas Powles, MD, PhD, FCRP, of Barts Cancer Centre, Queen Mary University of London, shares findings from the phase II RC48G001 trial of disitamab vedotin, an antibody-drug conjugate comprising a novel anti-HER2 antibody, disitamab, and an MMAE payload. The agent demonstrated “promising antitumor ...
Lisocabtagene Maraleucel in Relapsed or Refractory MZL
In a phase II trial (TRANSCEND FL) reported in The Lancet, Palomba et al found that the chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel was active in patients with relapsed or refractory marginal zone lymphoma (MZL). Study Details In the international multicenter trial, 67...
Perioperative Enfortumab Vedotin Plus Pembrolizumab in Cisplatin-Ineligible Bladder Cancer
As reported in The New England Journal of Medicine by Vulsteke et al, the phase III KEYNOTE-905/EV-303 trial has shown improved event-free and overall survival with the addition of perioperative enfortumab vedotin plus pembrolizumab to radical cystectomy in patients with muscle-invasive bladder...
Combined Tests Could Avoid Unnecessary Cystectomy, Study Finds
Combining a visual inspection of the bladder—systematic endoscopic evaluation—with a blood test to check for the presence of circulating tumor DNA (ctDNA) may accurately predict which patients with bladder cancer still have cancer in their bladder after treatment and which do not. These findings,...
Dietary Influence on Leukemia and Lymphoma Progression
In 2015, LH, a 66-year-old female, was diagnosed with chronic lymphocytic leukemia (CLL), Rai stage 0. Untreated, the woman’s lymphocyte count rose from 5,000/mm3 to 16,000/mm3 in 6 years (doubling time = 4.2 years). She was then advised to stop eating red meat (see the figure). Commercially...
Addition of Hormone Therapy to Postoperative Radiotherapy in Prostate Cancer
In an individual patient data meta-analysis reported at the 2026 ASCO Genitourinary Cancers Symposium (Abstract 305) and simultaneously published in The Lancet, Kishan et al found no apparent overall survival benefit of adding hormone therapy in patients undergoing postoperative radiotherapy after...
Fifteen-Year Results From SWOG S0016 Suggest Follicular Lymphoma May Be Curable
Advanced-stage follicular lymphoma is currently considered incurable. But a new analysis of long-term data from patients treated for the disease years ago with standard regimens of immunotherapy and a chemotherapy combination known as CHOP suggests that many of those patients can now be considered...
AI Model May Predict Cancer Risk in Patients With Colitis-Associated Low-Grade Dysplasia
In a new study published in Clinical Gastroenterology and Hepatology, Johnson et al reported that an automated artificial intelligence (AI) pipeline using large language models (LLMs) can accurately stratify future risk of advanced neoplasia in patients with colitis-associated low-grade dysplasia....
Can ctDNA Negativity Predict Metastasis-Free Survival in Muscle-Invasive Bladder Cancer?
Circulating tumor DNA (ctDNA) may be used to predict metastatic risk and identify which patients with muscle-invasive bladder cancer are more likely to benefit from a bladder-sparing treatment approach, according to findings from the RETAIN trials presented at the 2026 ASCO Genitourinary Cancers...
Adjuvant Pembrolizumab Plus Belzutifan in Patients With RCC at Increased Risk of Recurrence
Based on the results from the phase III KEYNOTE-564 study, adjuvant pembrolizumab is currently standard of care for patients with clear cell renal cell carcinoma at increased risk of recurrence following a nephrectomy. Now, the results from the phase III LITESPARK-022 study—which investigated the...
Advanced RCC: After Immunotherapy, Belzutifan Plus Lenvatinib or Cabozantinib?
At the 2026 ASCO Genitourinary Cancers Symposium, Robert J. Motzer, MD, of Memorial Sloan Kettering Cancer Center, presented results from the second interim analysis of the phase III LITESPARK-011 trial showing improved progression-free survival, higher objective response rate, and a trend toward...
Stereotactic vs Whole-Brain Radiation for Patients With Brain Metastases
Researchers have found that using a form of radiation therapy that targets individual tumors rather than whole-brain radiation is more optimal for patients with brain metastases, even if a larger number of tumors are present. These findings could help improve quality of life and cognitive function...
Skin Fluorescent Imaging Shows High Sensitivity, Specificity for Discriminating Melanoma Lesions
Skin fluorescent imaging showed high sensitivity and specificity for the discrimination of low- and high-risk lesions, demonstrating an alternative, noninvasive approach to melanoma biopsies, according to findings from a phase II trial published in JAAD International. “By identifying the molecular ...
Perioperative Enfortumab Vedotin Plus Pembrolizumab May Reduce Risk of Recurrence in Patients With Muscle-Invasive Bladder Cancer
The results from the randomized phase III KEYNOTE-B15/EV-304 study show that neoadjuvant and adjuvant enfortumab vedotin plus pembrolizumab significantly improved event-free survival, overall survival, and pathologic complete response rate in patients with muscle-invasive bladder cancer who were...
Medical Societies and More Respond to HHS RFI on AI Use in Clinical Care
In time for the assigned deadline of February 23, 2026, medical societies, companies, health-care systems, and more have responded to a request for information from the Department of Health and Human Services (HHS) regarding the use of artificial intelligence (AI) in clinical practice. The Request...
Advanced Nonsquamous NSCLC: FDA Grants Accelerated Approval to Zongertinib
On February 26, the U.S. Food and Drug Administration (FDA) granted accelerated approval to zongertinib (Hernexeos), a kinase inhibitor, for an expanded indication for adults with unresectable or metastatic nonsquamous non–small cell lung cancer (NSCLC) whose tumors have HER2 tyrosine kinase domain ...
Amar Kishan, MD, on Recurrent Prostate Cancer: Hormone Therapy and Postoperative Radiotherapy
Amar Kishan, MD, University of California, Los Angeles, discusses results from an individual patient data meta-analysis of randomized trials to quantify the benefit of adding hormone therapy to postoperative radiotherapy in patients with localized prostate cancer after radical prostatectomy...
Enrique Gallardo, MD, on mCRPC: Enzalutamide With or Without Radium-223
Enrique Gallardo, MD, of Parc Taulí University Hospital, presents final overall survival results from the EORTC 1333/PEACE-3 trial, which is a phase III trial evaluating the addition of radium-223 to enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) and bone...
Anna Clare Wilkins, PhD, MRCP, MBBChir, on Localized Prostate Cancer: MMAI-Derived Biomarker
Anna Clare Wilkins, PhD, MRCP, MBBChir, of The Institute of Cancer Research, discusses the external validation of a digital pathology-based multimodal artificial intelligence (MMAI)-derived prognostic biomarker using data from the phase III CHHiP trial. CHHiP evaluated conventional vs...
Scott Tyldesley, MD, FRCPC, on Localized Prostate Cancer: External Beam vs Brachytherapy Boost RT
Scott Tyldesley, MD, FRCPC, of BC Cancer Vancouver, reports on the 15-year survival analysis from the ASCENDE-RT trial, which randomly assigned patients to receive either prostate brachytherapy or the external-beam radiotherapy boost; both arms also received androgen-deprivation therapy....
‘Prostate Screening Saved My Life’—Is That Really True in Most Cases?
Prostate specific antigen (PSA) screening remains one of the most controversial of “standard” medical practices. As recently as the 2026 Super Bowl, one of the more unusual TV advertisements, sponsored by a pharmaceutical company with an interest in prostate cancer treatments, extolled the virtues ...
SABCS 2025: Top Picks From a Breast Cancer Specialist
Among the high-quality abstract presentations at the annual San Antonio Breast Cancer Symposium (SABCS), a few always stand out as particularly meritorious. Each year, The ASCO Post asks its Senior Deputy Editor, breast cancer specialist Jame Abraham, MD, FACP, to offer his top picks for most...
How the Outlook on Fertility Preservation for Patients With Cancer Is Improving
Each year in the United States, about 90,000 adolescents and young adults (AYAs), ages 15 to 39, are diagnosed with cancer,1 and they are immediately faced with myriad challenges and disruptions in their life stages, including psychosocial distress; interruptions in their education, career, and...
Nomogram for Metastasis-Directed SBRT in PSMA PET-Staged Oligorecurrent Prostate Cancer
In a European retrospective study (PORTAL) reported in The Lancet Oncology, Soeterik et al developed a nomogram for predicting androgen-deprivation therapy (ADT)–free survival with metastasis-directed stereotactic body radiotherapy (SBRT) in patients with prostate-specific membrane antigen (PSMA)...
Lung Cancer: Variability of Open-Source AI Models in EGFR Mutation Prediction
In a study reported in JAMA Oncology, Rakaee et al identified the accuracy of open-source artificial intelligence (AI) models in predicting the presence of EGFR mutations in samples from patients with lung adenocarcinoma, including according to ancestral subgroups. Study Details The study included...
Effect of Medicaid Expansion on Diagnosis, Treatment, and Outcomes in NSCLC
In a study reported in the Journal of Clinical Oncology, Zhao et al found that patients with non–small cell lung cancer (NSCLC) in Medicaid expansion states have had improvements in earlier diagnosis, early initiation of treatment, and survival. Study Details In the study, patients newly diagnosed...
Cancer Diagnoses During COVID-19 Pandemic: Impact on 1-Year Cause-Specific Survival
In a study reported in JAMA Oncology, Burus et al found that patients diagnosed with invasive cancer during 2020 and 2021—the first 2 years of the COVID-19 pandemic—had poorer 1-year cause-specific survival (CSS) rates vs patients diagnosed in the prepandemic years of 2015 to 2019. Study Details...
Long-Term Health Risks for Testicular Cancer Survivors Differ by Chemotherapy Regimen
Long-term effects on renal function, cardiovascular risk, and overall health burden in survivors of testicular cancer differed according to the chemotherapy regimen each patient received, according to the results of a large real-world study published in JNCCN—Journal of the National Comprehensive...
Intravesical Immunotherapy Shows Recurrence Control in BCG-Unresponsive Papillary-Only Non–Muscle-Invasive Bladder Cancer
Intravesical treatment with the investigational immunotherapy cretostimogene grenadenorepvec (CG0070) demonstrated “strong” high-grade recurrence-free survival rates in patients with high-risk, papillary-only, bacillus Calmette-Guérin (BCG)-unresponsive non–muscle-invasive bladder cancer, according ...
FDA Approves Encorafenib for Metastatic BRAF V600E–Mutated Colorectal Cancer
On February 24, the U.S. Food and Drug Administration (FDA) granted traditional approval to the kinase inhibitor encorafenib (Braftovi) in combination with cetuximab and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation, ...
I Used AI to Supplement My Oncology Care—It Reshaped My Treatment Plan
A year ago, I was confronting a series of symptoms—including rapid weight loss, abdominal distress, fatigue, and heart issues—that I couldn’t explain. I was just 60 years old and had been in good health, but now I sensed that something was seriously wrong. I made appointments with my primary care...
Leader in Global Cancer Care, Paul E. Goss, MD, PhD, FRCPC, FRCP Dies at 70
The oncology community is mourning the loss of Paul E. Goss, MD, PhD, FRCPC, FRCP, who died on December 19, 2025, at his home in Hopkinton, Massachusetts, from multiple system atrophy—a rare, progressive neurologic disorder with symptoms resembling those of Parkinson’s disease. He was 70 years ...
Introducing ASCO AI in Oncology
In February, ASCO and Conexiant launched ASCO AI in Oncology (ascoai.org), a digital platform dedicated to understanding how artificial intelligence (AI) is impacting cancer care. “Our goal with this hub is to empower oncology professionals with knowledge and the tools to adapt to a rapidly...
MRI-Based Neoadjuvant Chemotherapy Duration in HER2-Positive Breast Cancer
In a Dutch phase II study (TRAIN-3) reported in The Lancet Oncology, Louis et al found that magnetic resonance imaging (MRI)-guided optimization of duration of neoadjuvant chemotherapy was associated with favorable event-free survival in patients with stage II to III HER2-positive breast cancer....
ASCO’s First Living Guideline in GU Cancers Reflects Recent Practice-Changing Trials on Systemic Treatment of mCRPC
ASCO has published an updated guideline on systemic therapy for patients with metastatic castration-resistant prostate cancer (mCRPC), representing ASCO’s first Living Guideline in the area of prostate cancer and the first in any genitourinary (GU) cancer.1 “Guidelines will become less useful if...
Adjuvant Coformulated Vibostolimab Plus Pembrolizumab in High-Risk Stage IIB to IV Melanoma
In an interim analysis of a phase III trial (KEYVIBE-010) reported in The Lancet Oncology, Dummer et al found that adjuvant therapy with a coformulation of the anti-TIGIT antibody vibostolimab with pembrolizumab did not improve outcomes vs pembrolizumab alone in patients with resected high-risk...
AI-Selected Biomarker Guides First-Line Treatment Selection in Advanced Pancreatic Cancer
A computational histology–based artificial intelligence (AI) platform was able to identify a biomarker that could predict treatment benefit between two chemotherapy options for patients with advanced pancreatic cancer, according to the results of a study presented in a poster at the 2026 ASCO...
